SARS CoV 2 News and Research

RSS

Harnessing the natural potential of venom with the VOYAGER pipette

Venom, found in numerous species of reptiles, can cause intense pain and even paralysis but, paradoxically, can be used as medication to actually reduce pain.

From INTEGRA Biosciences 1 Feb 2021

Researchers develop mobile EKG device that can identify patients at risk of sudden cardiac death

Researchers from Mayo Clinic and AliveCor Inc. have been using artificial intelligence (AI) to develop a mobile device that can identify certain patients at risk of sudden cardiac death.

1 Feb 2021

Routine vaccinations in India disrupted by the COVID-19 pandemic

A team of researchers studied the disruptions in the vaccinations across India during the current pandemic.

1 Feb 2021

Inhaled single dose vaccine creates antibodies and prevents infection in rhesus macaques

Now, a new preprint research paper describes a chimpanzee adenovirus-vectored vaccine that, when administered intranasally in rhesus macaques, led to a robust immune response and demonstrated protection against infection by the virus that causes COVID-19, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The preprint is published on the bioRxiv server.

1 Feb 2021

India's Covaxin vaccine likely effective against UK SARS-CoV-2 variant: Study

A new preprint research paper, posted to the preprint server bioRxiv, presents data indicating that the Indian-made Covaxin vaccine candidate successfully neutralizes this variant, preventing infection when challenged by it.

1 Feb 2021

Complication of severe SARS-CoV-2 pneumonia results in persistent cortical blindness: Case report

A study recently published in the journal Cureus has described a case report of a coronavirus disease 2019 (COVID-19) patient who presented with pneumonia, posterior reversible encephalopathy syndrome (PRES), and persistent cortical blindness. A detailed clinical presentation of the patient is provided in the report.

31 Jan 2021

E484K mutation is potentially associated with SARS-CoV-2 adaptive fitness

A team of Brazilian scientists has recently conducted genomic and phylogenetic analyses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome to understand the viral evolution process better. Their analyses reveal that the E484K mutated variant of SARS-CoV-2 is present in three different lineages in four Brazilian regions and that the mutation may serve as a common solution for viral evolution.

31 Jan 2021

Lung mechanics and hypoxemia in COVID-19 patients with ARDS

To better understand how low blood oxygen level, or hypoxemia, and lung compliance varies in COVIDARDS and how they relate to disease outcomes, researchers developed a dataset of using more than 11,000 COVID-19 patients admitted to the hospital. A research paper published on the medRxiv* preprint server reports their results.

31 Jan 2021

SARS-CoV-2-specific T cells are key players in decreasing COVID-19 mortality

A recent US study, currently available on medRxiv preprint server, supports a beneficial rather than immunopathologic role for effector T-cells during serious infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) –

31 Jan 2021

Synergistic effect between NF-κB inhibitors and zinc in vitro reducing ACE2 expression

Researchers at National Taiwan University Hospital in Taipei have conducted a study demonstrating the potential effectiveness of a novel drug combination at reducing morbidity and mortality in coronavirus disease 2019 (COVID-19).

31 Jan 2021

Crystal structures of nanobodies could aid the design of COVID-19 therapies

Researchers at the National Institutes of Health in Bethesda, Maryland, have shown how certain synthetic nanobodies bind to the agent that causes coronavirus disease 2019 (COVID-19) – a development that could help inform the design of therapies.

31 Jan 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Study shows BioNTech-Pfizer COVID-19 vaccine's ability to neutralize UK viral variant

In a study evaluating the BioNTech-Pfizer COVID-19 vaccine's ability to neutralize the B.1.1.7 ("UK") viral variant, researchers found no loss of immune protection compared to that against the original Wuhan reference strain.

29 Jan 2021

Startup develops yeast-based test to detect the presence of SARS-CoV-2 in saliva

Incubated at the University of Campinas (UNICAMP) in the state of São Paulo, Brazil, and supported by São Paulo Research Foundation- FAPESP's Innovative Research in Small Business Program (PIPE), BIOinFOOD is a startup that is developing a rapid COVID-19 diagnostic test based on a patent application filed by students at UNICAMP's Genomics and Bioenergy Laboratory.

29 Jan 2021

Researchers explore adaptive immunity against human coronaviruses

A recent study shows that long-term adaptive immunity to endemic coronaviruses is widespread, but low in magnitude, and that it shares phenotypic features of spike-specific antibodies and T cell memory across all tested coronaviruses.

29 Jan 2021

What are the main drivers of COVID-19 vaccine hesitancy?

A study conducted in the UK has examined attitudes towards vaccination protecting against COVID-19 and highlighted some of the main drivers of willingness or unwillingness to be immunized.

29 Jan 2021

U.S. public divided over COVID-19 “immunity passports” idea

A nationally representative survey conducted in the U.S. suggests that the public is fairly evenly divided in its support of immunity certificates or “passports” to enable the selective lifting of restrictions placed on people during the COVID-19 pandemic.

29 Jan 2021

What are the natural origins of SARS-CoV-2?

Researchers from the UK and China performed a comprehensive analysis of horseshoe bat and pangolin Sarbecoviruses to shed light on the origins of SARS-CoV-2.

29 Jan 2021

New gene-based vaccine strategy receives grant from the Bill & Melinda Gates Foundation

The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation.

29 Jan 2021

Vitamins and other antiviral drugs may help combat COVID-19

Evidence is emerging that vitamin D - and possibly vitamins K and A - might help combat COVID-19. A new study from the University of Bristol published in the journal of the German Chemical Society Angewandte Chemie has shown how they - and other antiviral drugs - might work.

29 Jan 2021